Pfizer Inc (PFE) - Total Assets
Based on the latest financial reports, Pfizer Inc (PFE) holds total assets worth $207.62 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Pfizer Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Pfizer Inc - Total Assets Trend (1985–2025)
This chart illustrates how Pfizer Inc's total assets have evolved over time, based on quarterly financial data. Explore investment intensity of Pfizer Inc to see how much of total assets are deployed in long-term investments.
Pfizer Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Pfizer Inc's total assets of $207.62 Billion consist of 20.6% current assets and 79.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $1.14 Billion | 0.6% |
| Accounts Receivable | $11.87 Billion | 5.7% |
| Inventory | $10.65 Billion | 5.1% |
| Property, Plant & Equipment | $21.53 Billion | 10.3% |
| Intangible Assets | $53.73 Billion | 25.8% |
| Goodwill | $71.26 Billion | 34.2% |
Asset Composition Trend (1985–2025)
This chart illustrates how Pfizer Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Pfizer Inc (PFE) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pfizer Inc's current assets represent 20.6% of total assets in 2025, a decrease from 48.4% in 1985.
- Cash Position: Cash and equivalents constituted 0.6% of total assets in 2025, down from 9.3% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 59.0% of total assets, an increase from 2.0% in 1985.
- Asset Diversification: The largest asset category is goodwill at 34.2% of total assets.
Pfizer Inc Competitors by Total Assets
Key competitors of Pfizer Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
F:ZEGA
|
Germany | €114.46 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Novartis AG
SW:NOVN
|
Switzerland | CHF118.89 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
|
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
SHE:301096
|
China | CN¥3.80 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd
SHG:600671
|
China | CN¥464.88 Million |
Pfizer Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.25 | 1.26 | 1.37 |
| Quick Ratio | 0.94 | 0.96 | 1.12 |
| Cash Ratio | 0.00 | 0.04 | 0.07 |
| Working Capital | $8.47 Billion | $9.41 Billion | $13.15 Billion |
Pfizer Inc - Advanced Valuation Insights
This section examines the relationship between Pfizer Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.63 |
| Latest Market Cap to Assets Ratio | 0.69 |
| Asset Growth Rate (YoY) | -2.5% |
| Total Assets | $208.16 Billion |
| Market Capitalization | $143.68 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Pfizer Inc's assets below their book value (0.69x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Pfizer Inc's assets decreased by 2.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Pfizer Inc (1985–2025)
The table below shows the annual total assets of Pfizer Inc from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $208.16 Billion | -2.45% |
| 2024-12-31 | $213.40 Billion | -5.79% |
| 2023-12-31 | $226.50 Billion | +14.86% |
| 2022-12-31 | $197.21 Billion | +8.67% |
| 2021-12-31 | $181.48 Billion | +17.67% |
| 2020-12-31 | $154.23 Billion | -7.92% |
| 2019-12-31 | $167.49 Billion | +5.06% |
| 2018-12-31 | $159.42 Billion | -7.20% |
| 2017-12-31 | $171.80 Billion | +0.11% |
| 2016-12-31 | $171.62 Billion | +2.48% |
| 2015-12-31 | $167.46 Billion | -1.07% |
| 2014-12-31 | $169.27 Billion | -1.64% |
| 2013-12-31 | $172.10 Billion | -7.37% |
| 2012-12-31 | $185.80 Billion | -1.17% |
| 2011-12-31 | $188.00 Billion | -3.60% |
| 2010-12-31 | $195.01 Billion | -8.42% |
| 2009-12-31 | $212.95 Billion | +91.59% |
| 2008-12-31 | $111.15 Billion | -3.57% |
| 2007-12-31 | $115.27 Billion | +0.38% |
| 2006-12-31 | $114.84 Billion | -2.32% |
| 2005-12-31 | $117.56 Billion | -4.95% |
| 2004-12-31 | $123.68 Billion | +5.92% |
| 2003-12-31 | $116.78 Billion | +151.91% |
| 2002-12-31 | $46.36 Billion | +18.40% |
| 2001-12-31 | $39.15 Billion | +16.84% |
| 2000-12-31 | $33.51 Billion | +62.88% |
| 1999-12-31 | $20.57 Billion | +12.41% |
| 1998-12-31 | $18.30 Billion | +19.34% |
| 1997-12-31 | $15.34 Billion | +4.56% |
| 1996-12-31 | $14.67 Billion | +15.22% |
| 1995-12-31 | $12.73 Billion | +14.69% |
| 1994-12-31 | $11.10 Billion | +18.94% |
| 1993-12-31 | $9.33 Billion | -2.70% |
| 1992-12-31 | $9.59 Billion | -0.46% |
| 1991-12-31 | $9.63 Billion | +6.44% |
| 1990-12-31 | $9.05 Billion | +8.74% |
| 1989-12-31 | $8.32 Billion | +9.00% |
| 1988-12-31 | $7.64 Billion | +10.33% |
| 1987-12-31 | $6.92 Billion | +34.06% |
| 1986-12-31 | $5.16 Billion | +15.70% |
| 1985-12-31 | $4.46 Billion | -- |
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret b… Read more